Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA’s Structured Benefit-Risk Assessment Framework To Come Online In FY 2014

Executive Summary

Drug reviews will include a benefit-risk summary assessment that states the rationale for regulatory action on a drug or biologic application and explains how differences of opinion among reviewers were resolved.


Related Content

US FDA's Patrick Frey Joins List Of Agency Leadership Departures
US FDA's Benefit/Risk Framework Gets High Marks But Could Be Improved
PDUFA Renewal Negotiations: Industry On Offense, But Pricing Debate Could Hurt
PDUFA VI: FDA Proposes Expanding Sentinel, Real-World Safety Data Sources
Oral History Of Drug Development: FDA’s Califf Wants Woodcock, Temple To Share Their Stories
International Group Finds Harmony In Benefit-Risk Assessment Framework
FDA Pushes Back Against “Living” Benefit-Risk Assessment Management Plan
Benefit-Risk Assessment Framework Moves Toward Global Harmonization
PhRMA Testing Pilot Framework For Structured Benefit-Risk Assessment
PDUFA V Agreement Set In Four Areas, But Broad FDA/Industry Talks Continue





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts